Navigation Links
Nile Therapeutics Announces Filing of Annual and Quarterly Reports to Become Current on SEC Filings
Date:6/21/2013

SAN MATEO, Calif., June 21, 2013 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that is developing novel therapeutics for heart failure patients, today announced it has filed its Annual Report on Form 10-K for the year ended December 31, 2012, as well its Quarterly Reports on Form 10-Q for each of the quarters ended September 30, 2012 and March 31, 2013. As a result of these filings, Nile is now current with its obligations to file reports with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. More information on Nile can be found at http://www.nilethera.com.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
2. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
3. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
4. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
5. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
6. Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics
7. Prime Therapeutics receives prestigious Silver Anvil Award from Public Relations Society of America
8. Lineage Therapeutics Markets Authorized Generic Epinephrine Auto-Injector
9. Prime Therapeutics receives highest rating in 2013 customer satisfaction survey
10. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
11. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... the Jefferies 2014 Boston Healthcare Summit next week in ... on August 6, 2014 and will not be webcast. ... BioPharma manages a portfolio of patents and royalty assets, ... patents and license agreements with various biotechnology and pharmaceutical ...
(Date:7/30/2014)... Die Apex Medical Corporation (Apex, ... Atemtherapie- und Druckzonenprodukte, gibt bekannt, dass sie ... anfechten werden. Dieses hat entschieden, dass die ... ResMed verletze. Apex weist darauf hin, dass ... Patente von ResMed Anfechtungen wegen Nichtigkeit eingeleitet ...
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- The global microbial identification ... methods, applications, end users, and geographies. Genotypic technology ... microbial identification market. This favorable growth is attributed ... and the time required for microbial identification along ... Furthermore, genotypic methods have high applications in clinical ...
Breaking Medicine Technology:PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6
... , TAMPA, Fla. , April 26 ... today that Zirgan™ (ganciclovir ophthalmic gel) 0.15% is now commercially ... Drug Administration in September 2009 , is a topical ... (dendritic ulcers).   , ...
... April 26 Aton Pharma, Inc., a ... acquired the U.S. marketing rights to LODOSYN® (carbidopa) tablets ... use with carbidopa-levodopa or with levodopa in the treatment ... administration of lower doses of levodopa with reduced nausea ...
Cached Medicine Technology:Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 2Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 4
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people with diverticulitis and confirmed that many suffer psychological and physical symptoms long after their ... UCLA team led by Dr. Brennan Spiegel interviewed patients in great detail about the symptoms they experience weeks, months or even years ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased to ... will serve as chair. The board was voted upon ... Conference in Houston, Texas July 10-12. , “The ... us. From the rollout of the first EDNF Center ... Medical Center to our September physicians conference to a ...
(Date:7/30/2014)... OR (PRWEB) July 30, 2014 LTC Consumer, ... evaluate long term care insurance, features an Instant Quote tool ... Director and co-founder of LTC Consumer. Quotes are free and ... a click in only seven areas – including age, gender, ... on screen within seconds (you don’t need to enter any ...
(Date:7/30/2014)... The American Telemedicine Association (ATA) today ... (R-MS) and Roger Wicker (R-MS) for their efforts ... Medicare, Medicaid and Federal Communications Commission programs. , ... the Telehealth Enhancement Act as S. 2662, a ... introduced by Rep. Gregg Harper (R-MS) which already ...
(Date:7/30/2014)... July 30, 2014 Hospitals continually ... quality of care that their practitioners provide. During ... Andrew Rowe, discussed the importance of establishing effective ... physician performance and quality of care. , ... evaluation, Mr. Rowe elaborated on setting performance expectations, ...
Breaking Medicine News(10 mins):Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3
... risk factors are known to play a role in the ... known about the effect of body mass index and clustering ... ,Recently a study, published in the October issue of ... the relation between midlife body mass index and clustering of ...
... dysfunction (ED) is the inability of a man to achieve ... the needs of his partner. Most men experience this at ... are not psychologically affected by it. Some men, however, experience ... ,According to a new study in the October ...
... HIV vaccine is being jointly developed by Vical Pharmaceuticals and ... was developed by the scientistis in NIH and the Federal ... inserting the HIV genes//. ,Vical Inc. is a ... DNA delivery system, last month Vical has agreed to grant ...
... has been set up in Pakistani Kashmir to provide surgery ... ,The hospital was erected in just 2 hours//. The unit ... paramedical staff. The mobile unit was transported to Muzaffarabad, the ... medical facility has proved to be a boon to the ...
... up lately and this is causing harm to the patients ... tests, says a new study that was published online today ... of the University of Pittsburgh and colleagues studied 24,000 cases ... that erroneous diagnosis was made in nearly 1,300 cases. The ...
... is the most common cause of chronic liver disease ... NAFLD is currently available//. Understanding the specific effects of ... is important for patient counseling as well as for ... these issues, researchers from Mayo Clinic College of Medicine, ...
Cached Medicine News:Health News:Erectile dysfunction: an early warning sign of clinically silent coronary artery disease? 2Health News:Weight reduction by 5% may help in treating nonalcoholic fatty liver disease 2
... 20-year history, the VOYAGER RX Dilatation Catheter ... outcomes. It combines a new low profile, ... shaft,more flexible markers, and short taper balloon ... tortuous anatomy with even greater confidence, opening ...
... technology developed over Guidants 20-year history, the ... foundation for successful treatment outcomes. It combines ... with a lower profile shaft,more flexible markers, ... can cross tight and tortuous anatomy with ...
... Coat-A-Count AFP IRMA,is an ... measurement of,alpha-fetoprotein (AFP) in serum. ... vitro use in either of,two ... aid in the,management of patients ...
Enzyme immunoassay for the quantitative determination of ovarian cancer antigen CA125 in human serum...
Medicine Products: